Shanghai Haoyuan Chemexpress Co., Ltd. (SHA:688131)
62.72
+1.50 (2.45%)
Mar 10, 2026, 9:55 AM CST
SHA:688131 Revenue
In the year 2025, Shanghai Haoyuan Chemexpress had annual revenue of 2.87B CNY with 26.35% growth. Shanghai Haoyuan Chemexpress had revenue of 809.27M in the quarter ending December 31, 2025, with 24.29% growth.
Revenue
2.87B
Revenue Growth
+26.35%
P/S Ratio
4.53
Revenue / Employee
802.11K
Employees
3,826
Market Cap
12.98B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.87B | 598.16M | 26.35% |
| Dec 31, 2024 | 2.27B | 390.13M | 20.75% |
| Dec 31, 2023 | 1.88B | 521.99M | 38.44% |
| Dec 31, 2022 | 1.36B | 388.83M | 40.12% |
| Dec 31, 2021 | 969.23M | 334.12M | 52.61% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shenzhen Chipscreen Biosciences | 909.54M |
| Guangdong Taienkang Pharmaceutical | 674.49M |
| Zhejiang Jingxin Pharmaceutical | 4.00B |
| Beijing Aosaikang Pharmaceutical | 1.83B |
| Tibet Rhodiola Pharmaceutical Holding Co. | 2.72B |
| Henan Lingrui Pharmaceutical | 3.78B |
| Zhejiang Hisun Pharmaceutical | 9.84B |
| Zhejiang Hisoar Pharmaceutical | 1.86B |